Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-272-2 | CAS number: 56-40-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral: Hazard assessment is based on the weight of evidence from all available studies.
LD50 (oral) rat, male/female: 9550/7930 mg/kg bw
LD50 (oral) mice, male/female: 5640/4920 mg/kg bw
Inhalation:
No study required since exposure of humans via inhalation is unlikely based on the low vapour pressure, MMAD and exposure considerations. No hazard is expected based on the available data on the acute oral toxicity.
Dermal:
No study required since exposure of humans via skin is unlikely based on QSAR predictions with the available data on the physico-chemical properties of the substance. However, systemic toxic effects after acute dermal exposure are unlikely to occur based on the available data on the acute oral toxicity.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Test methods and performance uncertain, limited documentation available.
- Principles of method if other than guideline:
- The acute oral toxicity of glycine in mice was investigated.
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- mouse
- Strain:
- other: dd
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Age at study initiation: at 5 weeks of age
Weight at study initiation: No data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23±2 °C
- Humidity (%): 55±5°C
- Air changes (per hr): No data
- Photoperiod (hrs dark / hrs light): No data - Route of administration:
- oral: gavage
- Vehicle:
- physiological saline
- Details on oral exposure:
- Manufacture, supplier, source of supply: Iwai Chemicals Co.
Lot/batch No.: no data - Doses:
- more than 4 doses (unspecified)
- No. of animals per sex per dose:
- 5 - 10 animals/dose
- Control animals:
- not specified
- Details on study design:
- Duration of observation period following administration: 7 days
Frequency of observations and weighing: no data
Necropsy of survivors performed: yes
Other examinations performed: clinical signs - Statistics:
- Litchfield-Wilcoxon method
- Preliminary study:
- no data
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 4 920 mg/kg bw
- 95% CL:
- > 4 413 - < 5 486
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 5 640 mg/kg bw
- 95% CL:
- > 5 036 - < 6 317
- Mortality:
- no data
- Clinical signs:
- other: Decrease in in locomotor activity, slightly respiratory depression, piloerection and ptosis were observed in female and male mice at 15 to 35 min after dosing. Most of the animals stopped breathing after muscle weakness, cyanosis, circular movement, toni
- Gross pathology:
- Congestion in lungs and dot hemorrhage in glandular stomach were observed in some animals. No abnormal gross findings in the other organs were observed.
- Other findings:
- Organ weights: No data
Histopathology: No data
Potential target organs: No data
Other observations: No data - Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- CLP: not classified
DSD: not classified - Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Test methods and performance uncertain, limited documentation available.
- Principles of method if other than guideline:
- The acute oral toxicity of glycine in rats was investigated.
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Age at study initiation: at 7 weeks of age
Weight at study initiation: No data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23±2 °C
- Humidity (%): 55±5 °C
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): no data - Route of administration:
- oral: gavage
- Vehicle:
- physiological saline
- Details on oral exposure:
- Manufacture, supplier, source of supply: Iwai Chemicals Co.
Lot/batch No.: no data - Doses:
- more than 4 doses (unspecified)
- No. of animals per sex per dose:
- 5 - 10 animals/dose
- Control animals:
- not specified
- Details on study design:
- Duration of observation period following administration: 7 days
Frequency of observations and weighing:no data
Necropsy of survivors performed: yes
Other examinations performed: clinical signs - Statistics:
- Litchfield-Wilcoxon method
- Preliminary study:
- no data
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 7 930 mg/kg bw
- 95% CL:
- > 7 329 - < 8 580
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 9 550 mg/kg bw
- 95% CL:
- > 8 917 - < 10 228
- Mortality:
- no data
- Clinical signs:
- other: Decrease in in locomotor activity, slightly respiratory depression, piloerection and ptosis were observed in female and male rats at 15 to 35 min after dosing. Most of the animals stopped breathing after muscle weakness, cyanosis, circular movement, toni
- Gross pathology:
- Congestion in lungs and dot hemorrhage in glandular stomach were observed in some animals. No abnormal gross findings in the other organs were observed.
- Other findings:
- Organ weights: No data
Histopathology: No data
Potential target organs: No data
Other observations: No data - Interpretation of results:
- GHS criteria not met
- Conclusions:
- CLP: not classified
DSD: not classified
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The available information comprises studies which each alone are regarded insufficient for assessment (Klimisch score 4). However, the information from these independent sources is consistent and provides sufficient weight of evidence for hazard assessment leading to an endpoint conclusion in accordance with Annex XI, 1.2, of Regulation (EC) No 1907/2006. Therefore, the available information as a whole is sufficient to fulfil the standard information requirements set out in Annex VII, 8.5, of Regulation (EC) No 1907/2006.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral toxicity of glycine was investigated in male and female Wistar rats and DD mice. Five to ten animals were orally administered with a single dose of the test substance dissolved in physiological saline. The test doses were unspecified (more than 4 doses). The animals were observed for 7 days after administration. No data regarding mortalitiy and body weight development were given. Clinical signs of toxicity included a decrease in locomotor activity, slightly respiratory depression, piloerection and ptosis in female and male rats at 15 to 35 min after dosing. Most of the animals stopped breathing after muscle weakness, cyanosis, circular movement and tonic convulsion. Some rats became a comatose and stopped breathing without tonic convulsion. At gross pathology, congestion in lungs and dot hemorrhage in glandular stomach were observed in some animals. No abnormal gross findings in the other organs were observed. The oral LD50 in rats was estimated to be 9550 and 7930 mg/kg for males and females, respectively. For mice, the oral LD50 was estimated to be 5640 and 4920 mg/kg for males and females, respectively.
No data on acute inhalation and dermal toxicity is available.
Furthermore, intravenous and subcutaneous administration of glycine to rats revealed LD50 values of 2600 and 5240 mg/kg bw, respectively. Intravenous, subcutaneous and intraperitoneal application of glycine to mice resulted in LD50 values of 2510, 5480 and 4550 mg/kg bw, respectively.
Justification for classification or non-classification
The available data on acute oral toxicity of the test substance do not meet the criteria for classification according to Regulation (EC) 1272/2008 and Directive 67/548/EEC, and are therefore conclusive but not sufficient for classification.
No data is available for acute dermal and inhalation toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.